**9. Therapeutic Options**

Targeting gu<sup>t</sup> microbiota composition and metabolism may be appealing to tackle the immense burden of cardiovascular disease and fractures simultaneously. Human trials and experimental murine models have shown that nutrition (e.g., diets high in dietary fiber), probiotics, prebiotics, or supplementation of SCFAs may have beneficial effects on the skeleton [64,177,178] and cardiovascular system [179]. The potential of food as a medicine in the setting of CKD is huge, but many questions remain with regard to the optimal use of nutriceuticals. A 'one-size-fits-all' approach is unlikely to be successful. Omics, undoubtedly, will prove useful in personalizing nutritional therapy [180,181].

**Author Contributions:** Writing—original draft preparation, P.E.; writing—review and editing, P.E., S.D., K.V., B.M. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.
